Scarica l'app Stockscreener
23.39
3.96%
0.89
Dopo l'orario di chiusura:
23.44
0.05
+0.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$22.50
Aprire:
$23.05
Volume 24 ore:
1.91M
Relative Volume:
1.29
Capitalizzazione di mercato:
$3.96B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
129.94
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
-6.33%
1M Prestazione:
-3.47%
6M Prestazione:
-8.27%
1 anno Prestazione:
+28.09%
Intervallo 1D:
$22.14
$23.46
Intervallo di 1 settimana:
$22.14
$25.36
Portata 52W:
$13.40
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
23.39 | 3.81B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-05-21 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
Acadia Faces EU Setback On Trofinetide As Valuation Signals Diverge - Yahoo Finance
Is It Time To Revisit ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness? - Yahoo Finance
JP Morgan Raises Price Target for ACADIA Pharmaceuticals (ACAD) to $34 | ACAD Stock News - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
CHMP Setback Puts Acadia Rett Plans And Revenue Outlook In Focus - simplywall.st
ACAD Announces New Review Following CHMP’s Decision Against Rett Syndrome Medication in Europe - Bitget
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU - Finviz
Rafferty Asset Management LLC Boosts Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors - BioSpace
ACADIA (ACAD) -7.1%: EU Agency Rejects Rett Syndrome Drug - Trefis
Acadia Pharmaceuticals appoints Jonathan M. Poole to its board of directors - marketscreener.com
Acadia Pharmaceuticals Appoints Jonathan M. Poole To Its Board Of Directors - TradingView
ACADIA Stock (-7.1%): EU Regulator Rejects Rett Syndrome Drug Trofinetide - Trefis
Acadia, undaunted by recent EU rejection, seeks CHMP re-examination of Rett syndrome med Daybue - Fierce Pharma
Acadia Faces EU Setback On Trofinetide As Valuation Gap Widens - simplywall.st
Prolium’s $50M Series A raise; COUR Pharma touts liver drug follow-up - Endpoints News
ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: Navigating a 38.97% Potential Upside Amid Biotech Challenges - DirectorsTalk Interviews
Acadia receives negative EU opinion for Rett syndrome drug - Investing.com India
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Inside Biotech: Acadia seeks second look from European regulators on trofinetide - Proactive financial news
BofA cuts Acadia Pharmaceuticals stock price target on EU setback By Investing.com - Investing.com Canada
Acadia receives negative EU opinion for Rett syndrome drug By Investing.com - Investing.com Australia
BofA cuts Acadia Pharmaceuticals price target on pipeline review By Investing.com - Investing.com India
BofA cuts Acadia Pharmaceuticals price target on pipeline review - Investing.com
BofA cuts Acadia Pharmaceuticals stock price target on EU setback - Investing.com
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Teases Key Phase 2 Data in 2025 - MarketBeat
ACADIA Pharmaceuticals recently announced that, following a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding its Rett syndrome treatment Trofinetide, the company plans to formall - Bitget
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome - Yahoo Finance
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.'s (ACAD) Therapeutic Domains - Bitget
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.’s (ACAD) Therapeutic Domains - Yahoo Finance
Acadia Pharmaceuticals' Rett Syndrome Medication Less Likely to Receive EU Approval, RBC Says - marketscreener.com
HC Wainwright Brokers Decrease Earnings Estimates for ACAD - MarketBeat
ACADIA Pharmaceuticals Charts Growth Path After Record Year - TipRanks
Erste Asset Management GmbH Lowers Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals (ACAD) Margin Expansion To 36.5% Tests Bearish Earnings Narratives - Sahm
Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker - Seeking Alpha
Vanguard Group Inc. Reduces Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Lawsuit - GuruFocus
ACADIA Pharmaceuticals' Rett Syndrome Drug Faces EMA Setback - marketscreener.com
What is HC Wainwright's Estimate for ACAD Q3 Earnings? - MarketBeat
State of New Jersey Common Pension Fund D Purchases Shares of 85,821 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACAD Stock Price, Forecast & Analysis | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Decoding ACADIA Pharmaceuticals Inc (ACAD): A Strategic SWOT Ins - GuruFocus
Baker Bros. in ACADIA (NASDAQ: ACAD) secure long-term resale rights - Stock Titan
Will ACADIA Pharmaceuticals' (ACAD) 2025 Earnings Beat and 2026 Guidance Shift Its Growth Narrative? - Yahoo Finance
TD Cowen Raises Price Target for ACADIA Pharmaceuticals (ACAD) | - GuruFocus
TD Cowen Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat
Jefferies raises Acadia Pharmaceuticals stock price target on guidance By Investing.com - Investing.com South Africa
ACAD: RBC Capital Lowers Price Target While Maintaining Outperfo - GuruFocus
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth - Finviz
Royal Bank Of Canada Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $30.00 - MarketBeat
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
6.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):